# Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry

> **NCT07691034** · — · NOT_YET_RECRUITING · sponsor: **Odense University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma
- Minimal Residual Disease

## Interventions

- **DIAGNOSTIC_TEST:** Mass spectrometry

## Key facts

- **NCT ID:** NCT07691034
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-04
- **Primary completion:** 2029-01
- **Final completion:** 2035-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691034, "Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*